Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOCANO
2025-521006-18-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Oral Mucosal Carcinoma, sponsored by Karolinska University Hospital. Primary endpoints: Objective response rate, Pathological response rate and 1 more. Planned start May 2025; status: authorised.
02
Drugs
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2025-521006-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521006-18-00.